These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. Gaultney J; Benucci M; Iannazzo S; Nappi C; Sion K; Sabater FJ Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):409-17. PubMed ID: 26495961 [TBL] [Abstract][Full Text] [Related]
24. [Pyoderma gangrenosum associated with rheumatoid arthritis: a case report]. Beber AA; Knob CF; Shons KR; Neumaier W; da Silva JC; Monticielo OA Rev Bras Reumatol; 2014; 54(4):322-5. PubMed ID: 25627229 [TBL] [Abstract][Full Text] [Related]
25. Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept. Iwanaga N; Origuchi T; Terada K; Ueki Y; Kamo Y; Kinoshita N; Yonemitsu N; Kawashiri SY; Ichinose K; Tamai M; Nakamura H; Kawakami A Mod Rheumatol; 2014 Sep; 24(5):874-6. PubMed ID: 24611764 [No Abstract] [Full Text] [Related]
26. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795 [TBL] [Abstract][Full Text] [Related]
27. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196 [TBL] [Abstract][Full Text] [Related]
28. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. Kowalzick L; Bertolini J; Baumann C; Walther B; Truhm B; Eickenscheidt L J Dtsch Dermatol Ges; 2013 May; 11(5):447-9. PubMed ID: 23343137 [No Abstract] [Full Text] [Related]
29. New onset of rheumatoid vasculitis during abatacept therapy and subsequent improvement after rituximab. Carvajal Alegria G; Uguen A; Genestet S; Marcorelles P; Saraux A; Cornec D Joint Bone Spine; 2016 Oct; 83(5):605-6. PubMed ID: 27052429 [No Abstract] [Full Text] [Related]
30. An 82-year-old woman with new onset of multiple purple-reddish nodules during treatment with abatacept for rheumatoid arthritis. Ambrogio F; Laface C; Perosa F; Lospalluti L; Ranieri G; De Prezzo S; Prete M; Cazzato G; Guarneri F; Romita P; Foti C Intern Emerg Med; 2022 Nov; 17(8):2339-2341. PubMed ID: 35781779 [No Abstract] [Full Text] [Related]
31. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204 [TBL] [Abstract][Full Text] [Related]
32. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: report of 2 cases and review of the literature. Zonana-Nacach A; Jiménez-Balderas FJ; Martínez-Osuna P; Mintz G J Rheumatol; 1994 Jul; 21(7):1352-6. PubMed ID: 7966084 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Lahaye C; Soubrier M; Mulliez A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Mariette X; Gottenberg JE; Rheumatology (Oxford); 2016 May; 55(5):874-82. PubMed ID: 26822072 [TBL] [Abstract][Full Text] [Related]
34. A case of abatacept associated neutrophilic dermatosis and a review of the literature. Tiwari SM; Wood BA; Skender-Kalnenas T; Cook N Australas J Dermatol; 2014 Aug; 55(3):214-7. PubMed ID: 25117161 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
36. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Cinotti E; Labeille B; Perrot JL; Pallot-Prades B; Cambazard F Clin Exp Dermatol; 2014 Aug; 39(6):750-1. PubMed ID: 24984791 [No Abstract] [Full Text] [Related]
37. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Kim PS; Ho GY; Prete PE; Furst DE Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695 [TBL] [Abstract][Full Text] [Related]
38. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946 [TBL] [Abstract][Full Text] [Related]
39. Pyoderma gangrenosum treated with hyperbaric oxygen therapy. Wasserteil V; Bruce S; Sessoms SL; Guntupalli KK Int J Dermatol; 1992 Aug; 31(8):594-6. PubMed ID: 1428456 [TBL] [Abstract][Full Text] [Related]
40. Abatacept as add-on therapy for rheumatoid arthritis. Allison C Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]